Recce Advances Phase 3 Trial Plans as Cash Rebate Support Looms
RCE: $0.360 +9.09% · MC: $113M
Recce Pharmaceuticals says ethics approval is in place for an amended Australian Phase 3 study of its topical treatment for diabetic foot infections, while a Vietnamese patent expands its anti-infective intellectual property coverage. The company ended the quarter with about A$1 million in cash and expects an approximately A$7.5 million R&D tax rebate; it also reported receiving a further A$3.6 million rebate, bringing FY2025 rebates to approximately A$8.9 million. A completed share purchase plan and placement raised A$6.4 million in total, and the company issued shares under its employee incentive scheme.

Comments